BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show
October 20 2022 - 9:30AM
BioRestorative
Therapies, Inc. (the “Company” or
“BioRestorative”) (NASDAQ:
BRTX), a clinical stage company focused on stem cell-based
therapies, today announced that its CEO, Lance Alstodt, will be
interviewed on Famela and Friends Talk Radio Show to discuss the
Company’s progress and updates on its clinical development
pipeline.
BioRestorative is currently executing a Phase 2
trial to evaluate the safety and preliminary efficacy of a single
dose intradiscal injection of its lead cell therapy candidate,
BRTX-100. A total of up to 99 eligible patients will be randomized
at 15 centers in the United States to receive either the
investigational drug (BRTX-100) or control in a 2:1 fashion.
The radio show, which airs Sundays 7-8
pm on AM1170/FM96.1, is hosted by Famela Ramos along
with "friends" Kalina O'Connor and Wais Kaihani.
“We are excited to have the opportunity to be
guests of Famela and Friends”, said Lance Alstodt, the Company’s
CEO. “We look forward discussing the clinical advancements of the
company’s lead cell therapy candidate to treat chronic lumbar disc
disease as well as our Metabolic Program using cells derived from
brown adipose fat tissue.”
About BioRestorative
Therapies, Inc.
BioRestorative Therapies, Inc.
(www.biorestorative.com) develops therapeutic products using cell
and tissue protocols, primarily involving adult stem cells. Our two
core programs, as described below, relate to the treatment of
disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell
therapy candidate, BRTX-100, is a product formulated from
autologous (or a person’s own) cultured mesenchymal stem cells
collected from the patient’s bone marrow. We intend that the
product will be used for the non-surgical treatment of painful
lumbosacral disc disorders or as a complementary therapeutic to a
surgical procedure. The BRTX-100 production process utilizes
proprietary technology and involves collecting a patient’s bone
marrow, isolating and culturing stem cells from the bone marrow and
cryopreserving the cells. In an outpatient procedure, BRTX-100 is
to be injected by a physician into the patient’s damaged disc. The
treatment is intended for patients whose pain has not been
alleviated by non-invasive procedures and who potentially face the
prospect of surgery. We have commenced a Phase 2 clinical trial
using BRTX-100 to treat chronic lower back pain arising from
degenerative disc disease.
• Metabolic Program (ThermoStem®): We are
developing a cell-based therapy candidate to target obesity and
metabolic disorders using brown adipose (fat) derived stem cells to
generate brown adipose tissue (“BAT”). BAT is intended to mimic
naturally occurring brown adipose depots that regulate metabolic
homeostasis in humans. Initial preclinical research indicates that
increased amounts of brown fat in animals may be responsible for
additional caloric burning as well as reduced glucose and lipid
levels. Researchers have found that people with higher levels of
brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. You are cautioned that such
statements are subject to a multitude of risks and uncertainties
that could cause future circumstances, events or results to differ
materially from those projected in the forward-looking statements
as a result of various factors and other risks, including, without
limitation, those set forth in the Company's latest Form 10-K filed
with the Securities and Exchange Commission. You should consider
these factors in evaluating the forward-looking statements included
herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date
hereof and the Company undertakes no obligation to update such
statements.
CONTACT:Email: ir@biorestorative.com
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024